Rhumbline Advisers Immunity Bio, Inc. Transaction History

Rhumbline Advisers

$105 Billion
Q2 2024

A detailed history of Rhumbline Advisers transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 211,677 shares of IBRX stock, worth $1.15 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

211,677

Previous 186,875 13.27%

Holding current value

$1.15 Million

Previous $1 Million 33.3%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	BUY	$4.82 - $9.15 $119,545 - $226,938	24,802 Added 13.27%	211,677 $1.34 Million
Q1 2024 May 09, 2024	BUY	$3.23 - $6.17 $25,953 - $49,575	8,035 Added 4.49%	186,875 $1 Million
Q4 2023 Feb 08, 2024	BUY	$1.25 - $5.21 $46,306 - $193,004	37,045 Added 26.13%	178,840 $897,000
Q3 2023 Nov 09, 2023	SELL	$1.29 - $3.1 $6,901 - $16,585	-5,350 Reduced 3.64%	141,795 $239,000
Q2 2023 Aug 08, 2023	BUY	$1.53 - $6.41 $54,117 - $226,728	35,371 Added 31.65%	147,145 $409,000
Q1 2023 May 11, 2023	SELL	$1.35 - $4.78 $1,120 - $3,967	-830 Reduced 0.74%	111,774 $203,000
Q4 2022 Feb 14, 2023	BUY	$4.35 - $6.77 $13,384 - $20,831	3,077 Added 2.81%	112,604 $571,000
Q3 2022 Nov 10, 2022	BUY	$3.65 - $6.43 $31,006 - $54,622	8,495 Added 8.41%	109,527 $544,000
Q2 2022 Aug 11, 2022	BUY	$2.68 - $6.14 $34,596 - $79,261	12,909 Added 14.65%	101,032 $376,000
Q1 2022 May 12, 2022	SELL	$5.05 - $7.53 $10,882 - $16,227	-2,155 Reduced 2.39%	88,123 $494,000
Q4 2021 Feb 10, 2022	SELL	$5.67 - $10.18 $12,077 - $21,683	-2,130 Reduced 2.3%	90,278 $549,000
Q3 2021 Nov 12, 2021	BUY	$9.17 - $14.24 $29,967 - $46,536	3,268 Added 3.67%	92,408 $900,000
Q2 2021 Aug 05, 2021	BUY	$13.41 - $22.4 $687,249 - $1.15 Million	51,249 Added 135.25%	89,140 $1.27 Million
Q1 2021 May 06, 2021	BUY	$12.83 - $42.25 $486,141 - $1.6 Million	37,891 New	37,891 $900,000

Others Institutions Holding IBRX

# of Institutions

213

Shares Held

63.3M

Call Options Held

1.44M

Put Options Held

3.84M

View Full List

About ImmunityBio, Inc.

Ticker IBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 400,304,000
Market Cap $2.17B
Description
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...

More about IBRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Immunity Bio, Inc. Transaction History